ADMA
ADMA Biologics, Inc.
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
ADMA Biologics (ADMA) Stock: Buy, Sell, or Hold?
$13.19
+0.52 (+4.10%)
▲
5d:
+25.86%
30d:
+27.93%
90d:
+40.17%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 04, 2026
0d
Protect ADMA Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (28%)
Quality Score
25/100
Position
EXTENDED
30-Day Fair Range
$10.22 – $12.08
Position: EXTENDED
Forward P/E & Valuation
15.2x
STRETCHED
vs 11.7x historical avg
Wall Street Target
$18.00
+36.5% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$10.25 / $13.77
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: ADMA shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.65
Based on 6.1% avg growth
INTRINSIC VALUE TODAY
$8.47
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $13.19, which is considered extended relative to its 30-day fair value range of $10.22 to $12.08. From a valuation perspective, the stock is trading at a premium (Forward PE: 15.2) compared to its historical average (11.7). At these levels, the market is pricing in 9.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ADMA is in a strong uptrend. Immediate support is located at $10.25, while resistance sits at $13.77. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: ADMA scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.00 (+36.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADMA is in a strong uptrend. Immediate support is located at $10.25, while resistance sits at $13.77. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: ADMA scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.00 (+36.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.22 -
$12.08
Company Quality Score
25/100
(STRONG SELL)
Volume Confirmation
HIGH
Confidence Score
27.6%
Trading Range & Key Levels
30-Day Trading Range
$10.22 -
$12.08
Current vs Trading Range
EXTENDED
Support Level
$10.25
Resistance Level
$13.77
Current Trend
Strong Uptrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding ADMA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range (+9.2% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 36.5% below Wall St target ($18.00)
- NEUTRAL: Trading at premium valuation - market expects 9.2% growth which is achievable
- WARNING: Composite score 25/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
15.16
Wall Street Target
$18.00
(+36.5%)
Revenue Growth (YoY)
5.1%
Earnings Growth (YoY)
46.7%
Profit Margin
35.1%
Valuation Premium vs History
+9.2% premium
PE vs Historical
15.2 vs 11.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.2%
(market-implied from PE analysis)
1-Year Target
$14.40
(+9%)
2-Year Target
$15.73
(+19%)
3-Year Target
$17.18
(+30%)
3-Yr Target (if PE normalizes)
(PE: 15→12)
PE COMPRESSION
$13.25
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 8.1%)
$21.81
(+65%)
Base:
(SPY PE: 15.2, Growth: 8.1%)
$16.65
(+26%)
Bear:
(PE: 11.7, Growth: 8.1%)
$12.85
(-3%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 16.45 | Current EPS (TTM): $0.77
Bull Case
$15.75
(+19%)
Analyst growth 13.0%, PE expands to 18.1
Base Case
$14.32
(+9%)
Market implied 13.0%, PE stable at 16.5
Bear Case
$8.62
(-35%)
Severe decline -20.0%, PE contracts to 14.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share ADMA Analysis
Share this live ADMA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ADMA)
Bullish
7 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
6 msgs
24h retail stream
Last Tracked
Nov 12, 2026
Daily AI digest
AI Retail Discussion Summary:
ADMA Biologics' stock surged 20.9% after reporting better-than-expected Q3 earnings with robust demand for its lead product Asceniv. The company reiterated its full-year revenue expectation of at least $530 million.
Key Retail Themes:
Strong demand for Asceniv
Positive Q3 earnings report
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:10 PM ET
Data refreshes hourly during market hours. Next update: 9:10 PM
Data refreshes hourly during market hours. Next update: 9:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$107 | 33 SELL |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 43 HOLD |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ADMA Research Pages
